
ETF·NYSE
State Street SPDR S&P Biotech ETF (XBI)
- Net assets
- $10.36B
- Expense ratio
- 0.35%
- Yield
- 0.35%
- 52-week range
- $117.11 $169.89
What moved State Street SPDR S&P Biotech ETF (XBI)
Updated . Market figures as of November 20, 2026.
Was it the market or the fund?
On November 20, 2026, XBI fell 2.73%. The same day the S&P 500 (SPY) fell 3.64% and the Nasdaq 100 (QQQ) fell 5.67%.
The move was in line with the market. XBI's one-year beta to SPY is 1.18, so SPY's -3.64% would on average have meant -4.29% for XBI, close to what it did (1.6 percentage points less).
Over the last 20 sessions XBI is down 6.26% against -9.23% for SPY, 3.0 percentage points ahead of it.
The wider market on November 20, 2026: CNBC reported that the sell-off's breaking point came with Anthropic's initial public offering and heavier selling in Nvidia, which it named as the first of five forces behind the drop. (CNBC, November 20, 2026)
| That day | 5 sessions | 20 sessions | |
|---|---|---|---|
| XBI | -2.73% | -6.89% | -6.26% |
| S&P 500 (SPY) | -3.64% | -8.56% | -9.23% |
| Nasdaq 100 (QQQ) | -5.67% | -10.51% | -13.62% |
Calculated by CleaRank from daily closes. Beta is measured on the last year of daily returns against SPY. A description of what happened, not a forecast.
What changed since November 19, 2026
- CleaRank score: 49/100 on November 19, 2026, 45/100 on November 20, 2026 (still Hold).
- The price is below its 200-day average on November 20, 2026 ($140.18 against $143.45); on November 19, 2026 it was above it.
After moves like this
XBI fell 2.73% on November 20, 2026. Its typical daily move over the 60 trading days before was 1.15%. Between October 6, 2016 and November 20, 2026 (2,545 trading days) it fell at least that much in one day 196 times before.
| After the move | Cases | Median change | Range |
|---|---|---|---|
| 5 trading days later | 195 | +0.89% | -20.39% to +23.41% |
| 20 trading days later | 193 | +2.39% | -26.99% to +31.46% |
| 60 trading days later | 188 | +3.99% | -31.78% to +58.85% |
The close on November 20, 2026 is 17.32% below the highest close of the last 252 trading days ($169.55 on August 19, 2026). It is the lowest close since that high. Before that high, the last day it closed at least this far below its highest close of the 252 trading days to that day was August 11, 2025.
November 20, 2026 was the first close below the 200-day average ($143.45) since August 12, 2025.
These figures describe what happened after earlier moves in that period. They are not a forecast.
XBI ETF today, November 22, 2026: price, news and forecast
As of November 20, 2026, State Street SPDR S&P Biotech ETF (XBI) trades at $140.18. CleaRank rates it Hold with a score of 45/100.
XBI fell 2.73% on November 20, 2026, and closed below its 200-day average of $143.45 for the first time since August 12, 2025. The fund now sits 8.21% below its 50-day average and 6.32% below its 20-day average, and it is 6.32% below its highest close of the last 252 trading days, which was $169.55 on August 19, 2026. The drop matters because the fund has been losing ground for several weeks: CleaRank's score slid from 64 on November 13, 2026 to 45 today, and the rating moved from Buy to Hold on November 16, 2026. The one-year gain of 23.15% still stands, but the recent direction has turned down.
Why the fund fell below its long-term average
The close on November 20, 2026 was the first close below the 200-day average since August 12, 2025, and the price is now 2.28% below that line. The fund fell 2.73% that session on volume 12.0% above its average. This follows a run of weaker sessions: XBI fell 3.27% on November 12, 2026, closing at $151.20, and fell 3.10% on November 16, 2026, closing at $145.88. The fund also closed below its 50-day average on November 12, 2026. The price action is consistent, with each drop lower than the last.
What the momentum readings say
The 14-day RSI sits at 35.4, in the bearish zone but not oversold. The MACD line is negative. The 20-day average is at $149.64, and the 50-day average at $152.71 is above the 200-day average, which is still in an upward slope. That gap of 6.46% between the 50-day and 200-day averages shows the longer trend has not yet rolled over, even as the price has. The short-term picture is weaker than the longer one.
The fund's longer record
Over the past year, XBI is up 23.15%, and year to date it is up 14.97%. Over six months it is up 6.47%, but over three months it is down 15.42%, and over one month it is down 8.25%. The fund has been far from a steady climber. It holds 99.4% healthcare and 0.7% financial services, so its movements track the biotechnology sector closely. It is also an equal-weighted fund, which spreads its assets across many smaller biotech names rather than relying on a few large firms. Its expense ratio of 0.35% costs $35.00 a year on a $10,000 holding, and its distribution yield is 0.35%.
What the CleaRank score reflects
CleaRank rates the fund 45 out of 100, a Hold. The 1-year performance factor is strongly positive, and the cost factor is neutral. The trend and momentum factors are both negative, and momentum is the factor pulling the score down most. The score was 49 on November 19, 2026, after 56 on November 18, 2026, so it has fallen over the last several sessions.
CleaRank score 45/100 (Hold). 7 of 16 checks pass: trend 1 of 4, momentum 1 of 3, fund 3 of 5, track record 2 of 4.
About State Street SPDR S&P Biotech ETF
S. biotechnology companies. It seeks to track the S&P Biotechnology Select Industry Index, using an equal-weighted approach that gives relatively balanced representation across the portfolio rather than concentrating heavily in the largest firms. The fund is designed for investors looking for broad access to the biotech segment of the healthcare market through a single security. Its holdings typically span drug developers, therapeutic innovators, life sciences tools companies, and other biotechnology businesses across different market-cap sizes. S.
XBI ETF forecast 2026
The base case is that XBI keeps trading in a weak band while it works back toward its moving averages. For the trend to improve, the price needs to reclaim the 200-day average at $143.45 and then hold above the 20-day average at $149.64, which would show that the recent selling has eased. Until that happens, the trend reading stays negative, with the price below both the 50-day average at $152.71 and the 200-day average. A close back under the 52-week low of $117.11 would be a worse sign, since it would mean the fund has broken its one-year floor. Biotech funds like this one move with sector sentiment and interest-rate expectations, so a shift in those can change the picture quickly. The fund's typical daily move is 2.41%, so sharp swings in both directions are normal for it.
XBI support and resistance levels
Support sits at the 52-week low of $117.11, the nearest floor below the price and the level a fall would meet first. Resistance sits first at the 200-day average of $143.45, which the price just dropped below; a rebound would need to win it back. Next above is the 20-day average at $149.64, then the 50-day average at $152.71, and finally the 52-week high of $169.89. The 200-day average is the most closely watched level now, because the fund's position relative to it has changed in the last session.
| Level | What it is | Price | From the price |
|---|---|---|---|
| Resistance 4 | 52-week high | $169.89 | +21.2% |
| Resistance 3 | 50-day moving average | $152.71 | +8.9% |
| Resistance 2 | 20-day exponential average | $149.64 | +6.8% |
| Resistance 1 | 200-day moving average | $143.45 | +2.3% |
| Price | November 20, 2026 | $140.18 | |
| Support 1 | 52-week low | $117.11 | -16.5% |
Technical indicators
XBI technical analysis in depth
Volatility, momentum, trend strength and the price levels that matter for XBI, calculated by CleaRank from daily bars to November 20, 2026.
Volatility
On the 20-day Bollinger Bands (2 standard deviations) the bands run from $141.22 to $162.16 around a middle of $151.69, and XBI's close of $140.18 sits below the lower band, a stretched reading.
Band width is 13.8% of the price, in the middle of its range over the last 120 sessions.
The 14-day average true range is $4.921, or 3.5% of the price: a typical day's swing from high to low. A stop placed 1.5 ATR away would sit about 5.3% from the close.
Momentum and volume
The 14-day stochastic reads 2 (signal line 6): the close is near the bottom of its two-week range, an oversold zone.
The MACD line (12, 26) is -2.56 against a signal line (9) of -1.22, so the histogram is negative: momentum is weakening relative to its recent average. The MACD line crossed below its signal line 5 sessions ago.
Volume in the latest session was 1.1 times its 20-day average.
Trend strength
The 14-day ADX is 15, under 20: no strong trend in either direction, though sellers have the edge (+DI 15, -DI 29).
On the weekly chart the 10-week average ($151.27) is above the 40-week average ($143.45), a rising longer-term trend, and the weekly RSI is 43.
Key levels
The nearest resistance from the price history is $146.09 (+4.2%): the price turned here 4 times, most recently on November 6, 2026.
The nearest support is $138.21 (-1.4%): the price turned here 3 times, most recently on May 29, 2026.
The largest swing of the last 120 sessions ran up from $127.12 (June 3, 2026) to $169.89 (August 25, 2026); the nearest Fibonacci retracement to the price is the 61.8% level at $143.46.
Classic pivot points for the next session, from November 20, 2026: pivot $141.85, resistance $143.83 and $147.48, support $138.20 and $136.22.
| Level | Price | From the price | What it is |
|---|---|---|---|
| Resistance (swing high) | $162.89 | +16.2% | the price turned here 3 times, most recently on October 29, 2026 |
| Upper Bollinger Band | $162.16 | +15.7% | 20-day average + 2 standard deviations |
| Fibonacci 23.6% | $159.80 | +14.0% | retracement of the rise from $127.12 to $169.89 |
| Fibonacci 38.2% | $153.55 | +9.5% | retracement of the rise from $127.12 to $169.89 |
| Resistance (swing high) | $153.07 | +9.2% | the price turned here 3 times, most recently on September 24, 2026 |
| Fibonacci 50.0% | $148.51 | +5.9% | retracement of the rise from $127.12 to $169.89 |
| Pivot R2 (classic) | $147.48 | +5.2% | next-session level |
| Resistance (swing high) | $146.09 | +4.2% | the price turned here 4 times, most recently on November 6, 2026 |
| Pivot R1 (Fibonacci) | $144.00 | +2.7% | 38.2% of the last range above the pivot |
| Pivot R1 (classic) | $143.83 | +2.6% | next-session level |
| Fibonacci 61.8% | $143.46 | +2.3% | retracement of the rise from $127.12 to $169.89 |
| Pivot point | $141.85 | +1.2% | average of the last high, low and close |
| Lower Bollinger Band | $141.22 | +0.7% | 20-day average - 2 standard deviations |
| Price | $140.18 | close, November 20, 2026 | |
| Pivot S1 (Fibonacci) | $139.70 | -0.3% | 38.2% of the last range below the pivot |
| Support (swing low) | $138.21 | -1.4% | the price turned here 3 times, most recently on May 29, 2026 |
| Pivot S1 (classic) | $138.20 | -1.4% | next-session level |
| Fibonacci 78.6% | $136.27 | -2.8% | retracement of the rise from $127.12 to $169.89 |
| Pivot S2 (classic) | $136.22 | -2.8% | next-session level |
| Support (swing low) | $131.63 | -6.1% | the price turned here 2 times, most recently on February 25, 2026 |
| Support (swing low) | $127.22 | -9.2% | the price turned here 7 times, most recently on June 3, 2026 |
Swing levels are highs and lows the price turned at (the extreme of the five sessions either side), merged when they sit within 1.2 average true ranges of each other. Bollinger Bands (20, 2), ATR (14, Wilder), stochastic (14, 3), MACD (12, 26, 9), ADX (14, Wilder). Readings describe the chart; they are not a forecast.
XBI ETF price and trading
XBI share price
XBI fund facts and valuation
XBI Fund Facts
State Street SPDR S&P Biotech ETF is an exchange-traded fund that provides targeted exposure to U.S. biotechnology companies. It seeks to track the S&P Biotechnology Select Industry Index, using an equal-weighted approach that gives relatively balanced representation across the portfolio rather than concentrating heavily in the largest firms. The fund is designed for investors looking for broad access to the biotech segment of the healthcare market through a single security.
Sector weights
Total returns to Oct 31, 2026, as the fund family reports them
| Period | XBI |
|---|---|
| YTD | 28.00% |
| 1 month | -1.10% |
| 3 months | 6.06% |
| 1 year | 38.85% |
| 3 years | 33.31% |
| 5 years | 4.70% |
| 10 years | 10.94% |
Key statistics
XBI price history and drawdowns
Risk profile
Worst falls and recoveries
Growth of $10,000
Against the market: XBI trailed the S&P 500 over this period: $23,248 against $36,764.
A $10,000 investment in XBI in December 2016 would be worth about $23,248 today with dividends reinvested, compared with about $36,764 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
XBI price prediction 2030
XBI 2030 Scenarios (Monte Carlo)
CleaRank's simulation projects a price near $184 for XBI by 2030 in the base case, from $140 today (1.3x over 4 years). The 10th-percentile path ends near $81.23. These are outcomes of a Monte Carlo simulation run on XBI's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $99.71 | $150 | $226 | |
| 2028 | $90.09 | $161 | $286 | |
| 2029 | $84.68 | $172 | $349 | |
| 2030 | $81.23 | $184 | $416 |
XBI ETF forecast: questions people ask
XBI Forecast: Frequently Asked Questions
What is the XBI ETF forecast?
Is XBI a buy or sell today?
How far has XBI fallen from its high?
What does the fund hold?
How much does XBI cost to own each year?
What happened after similar one-day drops in the past?
How does XBI perform over longer periods?
How these figures are computed, and where the data comes from: CleaRank methodology.